| Id: | acc4906 |
| Group: | 2sens |
| Protein: | eNOS |
| Gene Symbol: | Nos3 |
| Protein Id: | Q62600 |
| Protein Name: | NOS3_RAT |
| PTM: | phosphorylation |
| Site: | Thr495 |
| Site Sequence: | GTGITRKKTFKEVANAVKISA |
| Disease Category: | Respiratory system diseases |
| Disease: | Pulmonary Thromboembolism |
| Disease Subtype: | Acute pulmonary thromboembolism (PTE) |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | Geldanamycin |
| Drug Info: | "Geldanamycin is a benzoquinone ansamycin antibiotic. It acts as a heat - shock protein 90 (Hsp90) inhibitor, which can disrupt the function of Hsp90 - client proteins and has potential applications in cancer treatment. " |
| Effect: | modulate |
| Effect Info: | "Geldanamycin (an Hsp90 inhibitor) inhibits the binding of Hsp90 to eNOS and enhances the phosphorylation of eNOS at the Thr495 site, thereby inhibiting eNOS activity, reducing NO production, increasing O?? production, disrupting the redox homeostasis of the pulmonary vascular endothelium, and exacerbating the pathological response of PTE." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 18852069 |
| Sentence Index: | 18852069_7-8 |
| Sentence: | "Together with the increase of NO production in lung homogenate of PTE rats at 1 h and its maximum reached at 3 d, geldanamycin treatment significantly attenuated the production of NO but augmented the production of O2(-) in the lungs of rats after PTE at indicated time length. These results suggest that geldanamycin may enhance eNOS phosphorylation at Thr-495 by inhibiting Hsp90, Hsp90 uncoupling eNOS protein results in increased eNOS-dependent O2(-) production." |
Sequence & Structure:
MGNLKSVGQEPGPPCGLGLGLGLGLCGKQGPASPAPEPSQAPVPPSPTRPAPDHSPPLTRPPDGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQSRPTQGPSPTEQLLGQARDFINQYYNSIKRSGSQAHEQRLQEVEAEVVATGTYQLRESELVFGAKQAWRNAPRCVGRIQWGKLQVFDARDCRTAQEMFTYICNHIKYATNRGNLRSAITVFPQRYAGRGDFRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELFTLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSSEIGMRDLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLYSYQLAKVTIVDHHAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHEALVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQHKSYKIRFNSVSCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFSPKRSWKRQRYRLSTQAESLQLLPRLTHVHRRKMFQATILSVENLQSSKSTRATILVRLDTGSQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPPSTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTYFLDITSPPSPRLLRLLSTLAEESSEQQELEALSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPLILTQLPLLQPRYYSVSSAPSAHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWMSQLKAGDPVPCFIRGAPSFRLPPDPNLPCILVGPGTGIAPFRGFWQDRLHDIEIKGLQPAPMTLVFGCRCSQLDHLYRDEVLDAQQRGVFGQVLTAFSRDPGSPKTYVQDLLRTELAAEVHRVLCLEQGHMFVCGDVTMATSVLQTVQRILATEGSMELDEAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWSFDPPTQETPGS
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
